ELOX
Eloxx Pharmaceuticals, Inc.Company Information
- Company Name
- Eloxx Pharmaceuticals, Inc.
- CIK
- CIK0001035354
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ELOX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ELOX
SEC filing data through
Insider Sentiment
- Last purchase
- 2021-11-29
- Last sale
- —
- Shares purchased (TTM)
- 20,294,441
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,549,714
- Shares outstanding
- 6,789,165
- Ownership
- 37.56%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -21.79%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
| Cash And Cash Equivalents At Carrying Value | 62 | 6 | 5 | 5 | ||||||
Assets Current | ||||||||||
| Assets Current | 63 | 9 | 5 | 6 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | ||||||
| Unbilled Contracts Receivable | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 2 | 0 | 1 | ||||||
| Property Plant And Equipment Net | - | - | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | - | - | 0 | 0 | ||||||
| Assets | 63 | 9 | 5 | 6 | ||||||
Liabilities And Stockholders Equity | ||||||||||
| Accounts Payable Current | 3 | 3 | 3 | 3 | ||||||
| Accrued Liabilities Current | 2 | 1 | 2 | 2 | ||||||
| Long Term Debt Current | 0 | 0 | 1 | 3 | ||||||
Liabilities Current | ||||||||||
| Liabilities Current | 17 | 16 | 17 | 23 | ||||||
| Deposit Liabilities Accrued Interest | 0 | 0 | 0 | - | ||||||
| Operating Lease Liability Current | - | - | 0 | 0 | ||||||
| Derivative Liabilities Current | - | - | 0 | 0 | ||||||
| Long Term Debt Noncurrent | - | - | 0 | 3 | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | ||||||
| Liabilities | - | - | 17 | 26 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 355 | 297 | 289 | 268 | ||||||
| Retained Earnings Accumulated Deficit | -309 | -304 | -301 | -289 | ||||||
| Stockholders Equity | 46 | -8 | -12 | -20 | ||||||
| Liabilities And Stockholders Equity | 63 | 9 | 5 | 6 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 100 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 4 | 5 | 5 | 3 | ||||||
| Shares Outstanding | 4 | 5 | 5 | 2 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEloxx Pharmaceuticals, Inc. (ELOX) — SEC Financial Statements & Analysis
Eloxx Pharmaceuticals, Inc. (ELOX) is a biological products, (no diagnostic substances) company, incorporated in DE. Eloxx Pharmaceuticals, Inc. trades on Nasdaq as: ELOX. Eloxx Pharmaceuticals, Inc. (ELOX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Eloxx Pharmaceuticals, Inc. carries a market cap of $94.23M, a P/E ratio of -7.95x, a P/B ratio of 2.03x, an enterprise value of $32.27M, and an EV/EBITDA multiple of -2.73x. On profitability, it posts a Return on Equity (ROE) of -85.16% and a Return on Assets (ROA) of -34.15%. Per share, it reports EPS of $-1.75, diluted EPS of $-1.75, free cash flow per share of $-3.32, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -46.20% year-over-year and EPS growth of -82.47% year-over-year. On the balance sheet, it maintains a current ratio of 3.74x, a quick ratio of 3.65x, working capital of $46.42M, a debt-to-equity ratio of 0.37x, a debt ratio of 0.27, free cash flow of $-22.57M (TTM), and net debt of $-61.96M. Figures sourced from SEC EDGAR.
- Market Cap
- $94.23M
- P/E TTM
- -7.95x
- EPS TTM
- $-1.75
- P/B TTM
- 2.03x
- ROE TTM
- -85.16%
- ROA TTM
- -34.15%
- Debt To Equity
- 0.37x
- Free Cash Flow TTM
- $-22.57M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Eloxx Pharmaceuticals, Inc. in?
Eloxx Pharmaceuticals, Inc. (ELOX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ELOX trade on?
Eloxx Pharmaceuticals, Inc. (ELOX) trades on the Nasdaq.
Where is Eloxx Pharmaceuticals, Inc. incorporated?
Eloxx Pharmaceuticals, Inc. is incorporated in DE.
When was Eloxx Pharmaceuticals, Inc. (ELOX)'s most recent SEC filing?
Eloxx Pharmaceuticals, Inc. (ELOX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is ELOX's market cap?
Eloxx Pharmaceuticals, Inc. (ELOX) has a market capitalization of $94.23M as of 2026-06-30.
What is ELOX's EPS (earnings per share)?
Eloxx Pharmaceuticals, Inc. (ELOX)'s trailing twelve month EPS is $-1.75 as of 2026-06-30.
What is ELOX's ROE (return on equity)?
Eloxx Pharmaceuticals, Inc. (ELOX)'s trailing twelve month Return on Equity (ROE) is -85.16% as of 2026-06-30.
What is ELOX's ROA (return on assets)?
Eloxx Pharmaceuticals, Inc. (ELOX)'s trailing twelve month Return on Assets (ROA) is -34.15% as of 2026-06-30.
What is ELOX's EV/EBITDA?
Eloxx Pharmaceuticals, Inc. (ELOX)'s trailing twelve month EV/EBITDA is -2.73x as of 2026-06-30.